Biological disease‐modifying drugs for rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2020 at "Prescriber"
DOI: 10.1002/psb.1836
Abstract: There are now nine biological disease‐modifying antirheumatic drugs (bDMARDs) available for the treatment of rheumatoid arthritis – seven monoclonal antibodies and two fusion proteins. This article summarises their indications, efficacy, place in therapy and adverse… read more here.
Keywords: drugs rheumatoid; disease modifying; biological disease; rheumatoid arthritis ... See more keywords
Disease-Modifying Drugs and Family Planning in People with Multiple Sclerosis: A Consensus Narrative Review from the Gulf Region
Sign Up to like & getrecommendations! Published in 2020 at "Neurology and Therapy"
DOI: 10.1007/s40120-020-00201-8
Abstract: Most disease-modifying drugs (DMDs) are contraindicated in pregnancy. Management of MS is especially challenging for pregnant patients, as withdrawal of DMDs leave the patient at risk of increased disease activity. We, a group of experts… read more here.
Keywords: planning; pregnancy; consensus; disease modifying ... See more keywords
Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting
Sign Up to like & getrecommendations! Published in 2020 at "Expert Review of Neurotherapeutics"
DOI: 10.1080/14737175.2021.1847085
Abstract: ABSTRACT Background: Relatively little is known about the use of disease-modifying drugs (DMDs) for multiple sclerosis (MS) in the population-based universal healthcare setting. This study aimed to describe the characteristics of a population-based cohort with… read more here.
Keywords: dmd; population based; disease modifying; cohort ... See more keywords
Effects of blood lipids and lipid‐modifying drugs on intracranial aneurysms
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Neurology"
DOI: 10.1111/ene.15471
Abstract: We used two‐sample Mendelian randomization (MR) to examine the effects of blood lipids and lipid‐modifying drugs on intracranial aneurysm (IA). read more here.
Keywords: drugs intracranial; lipids lipid; effects blood; blood lipids ... See more keywords
Qualitative factors shaping MS patients’ experiences of infusible disease-modifying drugs: a critical incident technique analysis
Sign Up to like & getrecommendations! Published in 2020 at "BMJ Open"
DOI: 10.1136/bmjopen-2020-037701
Abstract: Objective To explore factors shaping the experiences of patients with relapsing-remitting multiple sclerosis with infusible disease-modifying drugs in a hospital setting. Design and settings The critical incident technique served as a framework for collecting and… read more here.
Keywords: infusion; factors shaping; disease modifying; infusible disease ... See more keywords
[Esclerosis multiple. Lactancia. Lactante. Planificacion familiar. Posparto. Tratamiento modificador de la enfermedad.]
Sign Up to like & getrecommendations! Published in 2023 at "Revista de neurologia"
DOI: 10.33588/rn.7601.2022404
Abstract: INTRODUCTION Multiple sclerosis mainly affects women of childbearing age, and the pregnancy and postpartum period is of special interest because of the peculiarities of the disease course and the therapeutic consequences that derive from it.… read more here.
Keywords: period; modifying drugs; lactancia lactante; multiple lactancia ... See more keywords
Principles and functions of condensate modifying drugs
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Molecular Biosciences"
DOI: 10.3389/fmolb.2022.1007744
Abstract: Biomolecular condensates are compartmentalized communities of biomolecules, which unlike traditional organelles, are not enclosed by membranes. Condensates play roles in diverse cellular processes, are dysfunctional in many disease states, and are often enriched in classically… read more here.
Keywords: modifying drugs; functions condensate; condensate modifying; principles functions ... See more keywords
Emerging Molecular Targets for Anti-Epileptogenic and Epilepsy Modifying Drugs
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms24032928
Abstract: The pharmacological treatment of epilepsy is purely symptomatic. Despite many decades of intensive research, causal treatment of this common neurologic disorder is still unavailable. Nevertheless, it is expected that advances in modern neuroscience and molecular… read more here.
Keywords: emerging molecular; molecular targets; epilepsy modifying; targets anti ... See more keywords
Effects of Lipid-Modifying and Other Drugs on Lipoprotein(a) Levels—Potent Clinical Implications
Sign Up to like & getrecommendations! Published in 2023 at "Pharmaceuticals"
DOI: 10.3390/ph16050750
Abstract: The past few years have shown an ongoing interest in lipoprotein(a) (Lp(a)), a lipid molecule that has been proven to have atherogenic, thrombogenic, and inflammatory properties. Several lines of evidence, indeed, have demonstrated an increased… read more here.
Keywords: effects lipid; clinical implications; drugs lipoprotein; potent clinical ... See more keywords